FluoGuide announces positive top line result from the first part of the ongoing clinical phase I/II trial testing the safety and performance of FG001 in lightening up aggressive brain cancer
Copenhagen, Denmark, 01.04.2022 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that FG001 has been shown safe and well tolerated in 40 patients. The early evidence of efficacy has been demonstrated by strong illumination of brain tumors and histology data has now confirmed that the tissue lighted up is cancer. The optimal dose and time of FG001 administration has been decided to be 36 mg administered the evening before surgery.In total, 40 patients have been administered and FG001 has been shown safe and well tolerated (please see table). No serious drug related